"Analyst valuations
Following the positive Phase 3 trial results in December, the analysts covering Neuren significantly increased their current risk-adjusted valuations, with the range now $5.05 to $7.70 per share. In addition, Neuren was selected by Bioshares as one of the “Top 6 Picks for 2022” and was added to its model portfolio."
Ann: Q4 2021 quarterly activity and cash flow report, page-2
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.75 |
Change
0.000(0.00%) |
Mkt cap ! $1.757B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1290 | $14.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.07 | 435 | 1 |
View Market Depth
| Last trade - 09.57am 10/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable